BioCentury | Aug 14, 2019
Financial News

D&D raises $137M to fund inflammation tech out of JHU an associate professor of radiology at Johns Hopkins School of Medicine. Theraly's lead asset, TLY012...
BioCentury | Mar 19, 2019
Distillery Therapeutics

Agonizing TNFRSF10B for scleroderma

...a control IgG. Also in the model and in a genetic mouse model of scleroderma, TLY012...
...TNFRSF10B agonists in combination with other antifibrotic agents in the models. Theraly Fibrosis Inc. has TLY012...
Items per page:
1 - 2 of 2